文献速递肝病消化道肿瘤与早癌

肝硬化患者肝细胞癌监测时间覆盖比例

Proportion of Time Covered by Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2023-11-17

该回顾性队列研究纳入2008年1月至2022年12月美国2个大型医疗系统诊断的2027例肝细胞癌患者,其中331例在诊断前至少随访12个月。中位监测时间覆盖比例(PTC)为24.9%,仅16.0%接受半年一次影像监测、42.0%接受年度监测;PTC与早期检出、接受根治性治疗及总生存独立相关。

要点

  • 肝硬化患者肝细胞癌监测时间覆盖比例中位仅24.9%,半年一次影像监测者仅16.0%。
  • 接受消化科/肝病科管理者中位PTC为36.7%,未接受者为3.8%。
  • PTC<25%、25%-50%、>50%组中位生存分别为15.7、26.8、32.7个月。

核心结论

  • 肝硬化患者肝细胞癌监测的时间覆盖比例仍然很低,凸显需要多层面干预。

研究设计与样本

  • 回顾性队列研究,纳入2008年1月至2022年12月美国2个大型医疗系统诊断的2027例肝细胞癌患者,其中331例在诊断前至少随访12个月。

主要发现

  • 331例(51.4%为巴塞罗那临床肝癌分期0/A期)患者诊断前至少随访12个月,中位PTC为24.9%(四分位距1.1%-50.7%)。
  • 仅16.0%接受半年一次影像监测,42.0%接受年度监测;按24个月评估时,半年一次和年度监测分别降至6.3%和29.6%,中位PTC仍为24.9%。
  • 接受消化科/肝病科管理者中位PTC为36.7%,未接受者为3.8%,消化科/肝病科管理与PTC关联最强。
  • PTC与早期肝细胞癌检出、接受根治性治疗及总生存独立相关。
  • PTC<25%组(168例)、25%-50%组(69例)、>50%组(94例)中位生存分别为15.7、26.8、32.7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hepatocellular carcinoma (HCC) surveillance is associated with improved early tumor detection, but effectiveness is limited by underuse. We characterized adherence to HCC surveillance using proportion of time covered (PTC) and estimated its association with clinical outcomes among patients with cirrhosis. METHODS: We conducted a retrospective cohort study of patients diagnosed with HCC between January 2008 and December 2022 at 2 large US health systems. We characterized PTC by imaging in the 12 and 24 months before HCC diagnosis. We used multivariable logistic and Cox regression analyses to assess the association between PTC and early HCC detection, receipt of curative treatment, and overall survival. RESULTS: Among 2,027 patients with HCC, 331 (51.4% Barcelona Clinic Liver Cancer 0/A) had been followed up for at least 12 months before diagnosis. The median PTC was 24.9% (interquartile range 1.1%-50.7%), with only 16.0% having semiannual imaging and 42.0% having annual surveillance. Semiannual and annual surveillance decreased to 6.3% and 29.6% when assessed over 24 months, although the median PTC remained unchanged at 24.9%. Receipt of gastroenterology/hepatology care had the strongest association with PTC, with median PTC of 36.7% and 3.8% for those with and without gastroenterology/hepatology care, respectively. PTC was independently associated with improved early HCC detection, curative treatment receipt, and overall survival. The median survival was 15.7, 26.8, and 32.7 months among those with PTC of <25% (n = 168 patients), PTC 25%-50% (n = 69 patients), and PTC >50% (n = 94 patients), respectively. DISCUSSION: The proportion of time covered by HCC surveillance in patients with cirrhosis remains low, highlighting a need for multilevel interventions.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Daher D, Seif El Dahan K, Yekkaluri S, et al. Proportion of Time Covered by Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis. Am J Gastroenterol. 2023. PMID: 37975606. doi:10.14309/ajg.0000000000002596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。